Market Cap 14.42M
Revenue (ttm) 4.72M
Net Income (ttm) -3.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -71.61%
Debt to Equity Ratio 0.00
Volume 172,400
Avg Vol 58,710
Day's Range N/A - N/A
Shares Out 6.71M
Stochastic %K 100%
Beta 0.72
Analysts Sell
Price Target $5.00

Company Profile

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune su...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9824 5254
Fax: 61 3 9822 7735
Address:
62 Lygon Street, Level 3 Carlton South, Carlton, Australia
Baseball89
Baseball89 Oct. 7 at 1:29 AM
$IMRN I'm getting ready for this baby. I did my DD. Let's hope we all make bank.
0 · Reply
Feverrrr
Feverrrr Oct. 6 at 9:41 PM
$IMRN 🚀
0 · Reply
makedatbread88
makedatbread88 Oct. 6 at 9:28 PM
$IMRN hmmm abnormal volume, 1 week accumulation, and catalyst this month One to watch thanks to one of my followers for bringing this one to my attention
0 · Reply
HungerGains
HungerGains Oct. 6 at 7:57 PM
$IMRN patience
0 · Reply
Trash_Star
Trash_Star Oct. 5 at 10:22 PM
$IMRN this stock sucks I’m selling first thing in the morning and buying some eth
1 · Reply
Baazigar30
Baazigar30 Oct. 4 at 6:02 PM
$IMRN This where I bought and passed already 2 months. I don’t like waiting that long but had to . Hope quick spike hard cause flippers may enter and exit with slow move imo . With quick spike early birds can cash out and those flippers may stuck as bag holders 😂 .
1 · Reply
Timtheshark
Timtheshark Oct. 4 at 8:07 AM
$IMRN ATM loaded yesterday (~$2.85M) just days ahead of 3 major Oct catalysts & right after bullish CEO letter to maximize headroom - Looks like bullish prep to sell on upcoming rally 👀 and still tiny amount, asymmetry intact 🚀🤞
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 10:07 PM
$IMRN Great piece that accurately captures IMRN's current position. So if you want to refresh your understanding of IMRN or learn about IMRN for the first time, this is essential reading. https://beyondspx.com/quote/IMRN/analysis/immuron-s-polyclonal-power-unlocking-value-in-gut-health-and-beyond-nasdaq-imrn
1 · Reply
TraderJay85
TraderJay85 Oct. 3 at 8:26 PM
$IMRN small loss 2 cents 👎 $KUKE broke even 🤷‍♂️ $ICG Broke even 🤷‍♂️ $NB went to 8.37 🔥 Had 10 Big wins, 5 tiny losses, and 3 still holding, from last nights PMM'S list. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER.
0 · Reply
Trash_Star
Trash_Star Oct. 3 at 6:44 PM
$IMRN this stock blows Winnie
0 · Reply
Latest News on IMRN
Immuron Letter to Shareholders – Projects Update

Oct 2, 2025, 6:00 AM EDT - 5 days ago

Immuron Letter to Shareholders – Projects Update


Immuron partners with InvestorHub

Aug 26, 2025, 10:29 PM EDT - 5 weeks ago

Immuron partners with InvestorHub


Immuron Letter to Shareholders: Projects Update

May 30, 2025, 6:00 AM EDT - 4 months ago

Immuron Letter to Shareholders: Projects Update


Immuron Travelan® highest sales in history

Apr 10, 2025, 6:00 PM EDT - 6 months ago

Immuron Travelan® highest sales in history


Immuron Travelan® continued strong sales growth

Jan 17, 2025, 6:00 AM EST - 9 months ago

Immuron Travelan® continued strong sales growth


Immuron Announces Travelan® Clinical Trial Update

Jan 14, 2025, 6:00 AM EST - 9 months ago

Immuron Announces Travelan® Clinical Trial Update


Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Sep 5, 2024, 11:54 AM EDT - 1 year ago

Immuron Plans Phase 2 Trial for IMM-529 following FDA review


Immuron requests pre-IND meeting for IMM-529 with FDA filing

Jul 2, 2024, 6:00 AM EDT - 1 year ago

Immuron requests pre-IND meeting for IMM-529 with FDA filing


Immuron Board Changes

May 31, 2024, 6:00 AM EDT - 1 year ago

Immuron Board Changes


Immuron CEO Steven Lydeamore to present at Peak Sky High

May 31, 2024, 6:00 AM EDT - 1 year ago

Immuron CEO Steven Lydeamore to present at Peak Sky High


Immuron Limited to Present at the Emerging Growth Conference

May 7, 2024, 6:00 AM EDT - 1 year ago

Immuron Limited to Present at the Emerging Growth Conference


Immuron Director Resignation

May 3, 2024, 6:00 AM EDT - 1 year ago

Immuron Director Resignation


Immuron to host Live Virtual Event

Apr 15, 2024, 6:00 AM EDT - 1 year ago

Immuron to host Live Virtual Event


Immuron Travelan® sales continued strong growth

Apr 10, 2024, 6:00 AM EDT - 1 year ago

Immuron Travelan® sales continued strong growth


Immuron Presentation Australian Biologics Festival 2024

Feb 21, 2024, 6:00 AM EST - 1 year ago

Immuron Presentation Australian Biologics Festival 2024


Immuron achieves record Travelan® sales

Feb 13, 2024, 6:00 AM EST - 1 year ago

Immuron achieves record Travelan® sales


Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Feb 8, 2024, 6:00 AM EST - 1 year ago

Immuron CEO, Steven Lydeamore Investor Webinar Presentation


Immuron achieves record half yearly Travelan® sales

Jan 16, 2024, 6:00 AM EST - 1 year ago

Immuron achieves record half yearly Travelan® sales


Immuron Clinical Trials Update

Dec 22, 2023, 6:00 AM EST - 1 year ago

Immuron Clinical Trials Update


Immuron CEO Steven Lydeamore Investor Webinar Presentation

Nov 13, 2023, 6:00 PM EST - 2 years ago

Immuron CEO Steven Lydeamore Investor Webinar Presentation


Immuron CEO Steven Lydeamore presented at AusBioInvest

Oct 30, 2023, 7:21 AM EDT - 2 years ago

Immuron CEO Steven Lydeamore presented at AusBioInvest


Immuron Announces Travelan® Clinical Study Cohort 2 commences

Oct 18, 2023, 6:00 AM EDT - 2 years ago

Immuron Announces Travelan® Clinical Study Cohort 2 commences


Immuron achieves record quarterly Travelan® sales

Oct 11, 2023, 6:00 AM EDT - 2 years ago

Immuron achieves record quarterly Travelan® sales


Immuron achieves record monthly Travelan® sales

Sep 13, 2023, 6:00 AM EDT - 2 years ago

Immuron achieves record monthly Travelan® sales


Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright


Immuron CEO, Steven Lydeamore to present at Bioshares

Jul 24, 2023, 6:00 AM EDT - 2 years ago

Immuron CEO, Steven Lydeamore to present at Bioshares


Immuron FY23 Sales increase 136% on FY22 Sales

Jul 5, 2023, 6:00 AM EDT - 2 years ago

Immuron FY23 Sales increase 136% on FY22 Sales


Immuron Chairman Transition

Jun 30, 2023, 6:00 AM EDT - 2 years ago

Immuron Chairman Transition


Immuron Business Update: Letter to Shareholders

Jun 22, 2023, 6:00 AM EDT - 2 years ago

Immuron Business Update: Letter to Shareholders


Immuron Initiates Recruitment of Travelan® Clinical Study

May 30, 2023, 6:00 AM EDT - 2 years ago

Immuron Initiates Recruitment of Travelan® Clinical Study


Baseball89
Baseball89 Oct. 7 at 1:29 AM
$IMRN I'm getting ready for this baby. I did my DD. Let's hope we all make bank.
0 · Reply
Feverrrr
Feverrrr Oct. 6 at 9:41 PM
$IMRN 🚀
0 · Reply
makedatbread88
makedatbread88 Oct. 6 at 9:28 PM
$IMRN hmmm abnormal volume, 1 week accumulation, and catalyst this month One to watch thanks to one of my followers for bringing this one to my attention
0 · Reply
HungerGains
HungerGains Oct. 6 at 7:57 PM
$IMRN patience
0 · Reply
Trash_Star
Trash_Star Oct. 5 at 10:22 PM
$IMRN this stock sucks I’m selling first thing in the morning and buying some eth
1 · Reply
Baazigar30
Baazigar30 Oct. 4 at 6:02 PM
$IMRN This where I bought and passed already 2 months. I don’t like waiting that long but had to . Hope quick spike hard cause flippers may enter and exit with slow move imo . With quick spike early birds can cash out and those flippers may stuck as bag holders 😂 .
1 · Reply
Timtheshark
Timtheshark Oct. 4 at 8:07 AM
$IMRN ATM loaded yesterday (~$2.85M) just days ahead of 3 major Oct catalysts & right after bullish CEO letter to maximize headroom - Looks like bullish prep to sell on upcoming rally 👀 and still tiny amount, asymmetry intact 🚀🤞
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 10:07 PM
$IMRN Great piece that accurately captures IMRN's current position. So if you want to refresh your understanding of IMRN or learn about IMRN for the first time, this is essential reading. https://beyondspx.com/quote/IMRN/analysis/immuron-s-polyclonal-power-unlocking-value-in-gut-health-and-beyond-nasdaq-imrn
1 · Reply
TraderJay85
TraderJay85 Oct. 3 at 8:26 PM
$IMRN small loss 2 cents 👎 $KUKE broke even 🤷‍♂️ $ICG Broke even 🤷‍♂️ $NB went to 8.37 🔥 Had 10 Big wins, 5 tiny losses, and 3 still holding, from last nights PMM'S list. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER.
0 · Reply
Trash_Star
Trash_Star Oct. 3 at 6:44 PM
$IMRN this stock blows Winnie
0 · Reply
Baseball89
Baseball89 Oct. 3 at 1:14 AM
$IMRN market makers need to send out alerts. This is solid Let's get this thing rolling.
1 · Reply
TraderJay85
TraderJay85 Oct. 3 at 12:06 AM
PRE-MARKET MOVERS (PMM) Last nights PMM we hit 15 out of 18. Other 3 still playable above stop. $IMRN 2.15 Stop $KUKE .60 $ICG 1.89 Never hold under support. if it goes below then sell. Jump back in if it comes back to last support like YDES. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER ❤️
0 · Reply
Baazigar30
Baazigar30 Oct. 2 at 11:34 PM
$IMRN Moving that’s nice but this is my second stock annoyed holding that long . Anyway here to make 💰. Waiting for my target .
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 2 at 4:58 PM
Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates $IMRN https://stocktwits.com/news/equity/markets/immuron-stock-rallies-after-ceo-dismisses-us-pharma-tariff-impact/chCrSSWR3f5
0 · Reply
Baseball89
Baseball89 Oct. 2 at 2:12 PM
$IMRN this can easily go to $15 today. Solid results. Low float
1 · Reply
Timtheshark
Timtheshark Oct. 2 at 1:52 PM
$IMRN Solid update today - on track to beat FY24 Q1 record sales. Oct topline confirmed - will request FDA End-of-Phase-2 meeting for Travelan afterward. If data hit, aim is DoD guideline inclusion → potential purchases across units 🚀
0 · Reply
Baseball89
Baseball89 Oct. 2 at 11:41 AM
$IMRN We need some market makers to put some alerts out to get for everybody a heads up so they know about it
0 · Reply
JamesPond007
JamesPond007 Oct. 2 at 11:22 AM
0 · Reply
JamesPond007
JamesPond007 Oct. 2 at 11:18 AM
$IMRN Out in the wasteland, where time rusts like metal left to burn, IMRN crawls from the dust— a lazy koala no more, but a beast awakened after endless storms. Engines cough, sirens howl, the market waits with parched tongues, thirsting for news, chained to the long delays. At last— the trial update roars across the sand, a cracked megaphone on a shattered tower: “Here it comes… after all this silence.” Traders strap in, wheels spin, the ticker sputters like gasoline fire— uncertain, dangerous, but alive. No puppets here, just headlights in the dust, a convoy of hope chasing one koala who finally decided to wake up.
1 · Reply
DARKP00L
DARKP00L Oct. 2 at 11:04 AM
$IMRN 06:38 on Oct. 02 2025 Immuron Says It Is On Track To Exceed FY24 First-Quarter Sales; To Request End Of Phase 2 Meeting With FDA For IMM-124E #tradeideas
0 · Reply
PETER__BANKS
PETER__BANKS Oct. 2 at 11:00 AM
$IMRN Immuron Letter to Shareholders – Projects Update Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical products Travelan® Clinical Study: Topline results from the Travelan® clinical study conducted by Uniformed Services University are anticipated in October 2025 IMM-529 Regulatory Milestone: Immuron plans to submit an Investigational New Drug (IND) application to the U.S. FDA for IMM-529 (Clostridiodes difficile infection) in mid-October 2025 ProIBS® Commercial Launch: The Australian Launch of ProIBS® is on track for Q4 of calendar year 2025 IMM-986 Pre-Clinical Progress: Initial pre-clinical research studies for IMM-986, targeting Vancomycin-resistant Enterococci (VRE), are anticipated to be completed by year-end 2025
0 · Reply
DARKP00L
DARKP00L Oct. 2 at 10:47 AM
$IMRN 06:38 on Oct. 02 2025 Immuron Says It Is On Track To Exceed FY24 First-Quarter Sales; To Request End Of Phase 2 Meeting With FDA For IMM-124E #tradeideas
0 · Reply